Bimetinib, with its unique mechanism of action, precisely targets the RAS/RAF/MEK/ERK signaling pathway, bringing new hope to cancer patients carrying BRAFV600E or V600K gene mutations.

1、 Drug name

1. Product Name: MEKTOVI

2. Common name: Binimetinib

2、 Indications

The combination of Bimetinib and Conafenib is used to treat melanoma patients with unresectable or metastatic BRAFV600E or V600K mutations, which must be confirmed through FDA approved testing methods.

3、 Specifications and characteristics

Specification: 15mg tablets

4、 Main components

Active ingredient: Binimetinib

5、 Usage and dosage

1. Recommended dosage: 45mg each time, twice daily, in combination with Conafenib until disease progression or unacceptable toxicity occurs.

2. Administration method: Oral, can be taken with or without food.

6、 Dose adjustment

1. For patients who experience adverse reactions, the dosage can be adjusted according to the severity, with the first dose reduced to 30mg twice a day. If it is still intolerable, the medication will be permanently discontinued.

2. For patients with moderate or severe liver injury, the recommended dose is 30mg twice daily.

7、 Medication precautions

1. Before and after meals: can be taken with or without food.

2. Missed dose: If a dose is missed once and the time until the next dose exceeds 6 hours, it should be taken as soon as possible; If it is less than 6 hours, skip the missed dose and take the next dose at the regular time.

3. Vomiting: If vomiting occurs after taking medication, there is no need to take the next dose as usual.

8、 Medication for special populations

1. Pregnant women: May cause fetal harm, pregnant women are prohibited from using it. Female patients should use effective contraceptive measures during treatment and for at least 30 days after the last dose of medication.

2. Breastfeeding women: It is recommended not to breastfeed during the treatment period and within 3 days after the last dose of medication.

3. Children: Safety and efficacy have not yet been established.

4. Elderly patients: There is no significant difference in safety and efficacy between elderly patients (≥ 65 years old) and younger patients.

9、 Adverse reactions

1. The most common adverse reactions (≥ 25%) include fatigue, nausea, diarrhea, vomiting, and abdominal pain.

2. Other serious adverse reactions include cardiomyopathy, venous thromboembolism, ocular toxicity (such as serous retinopathy, retinal vein occlusion, uveitis), interstitial lung disease, hepatotoxicity, rhabdomyolysis, and bleeding.

10、 Contraindications

There are no specific contraindications.

11、 Drug interactions

No clinically significant interactions were observed between the drug and bimetinib.

12、 Storage method

Stored in an environment of 20 ° C to 25 ° C (68 ° F to 77 ° F), the allowable temperature fluctuation range is 15 ° C to 30 ° C (59 ° F to 86 ° F).

Binimetinibinformation